Last update 03 Jan 2025
Amifostine
Last update 03 Jan 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Amifostine (USP), Amifostine anhydrous, Amifostine hydrate + [20] |
Target |
Mechanism TNSALP modulators(Alkaline phosphatase, tissue-nonspecific isozyme modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (08 Dec 1995), |
RegulationAccelerated Approval (US), Orphan Drug (US) |
Login to view timeline
Structure
Molecular FormulaC5H21N2O6PS |
InChIKeyTXQPXJKRNHJWAX-UHFFFAOYSA-N |
CAS Registry112901-68-5 |
Related
32
Clinical Trials associated with AmifostineA Phase II Trial of Capecitabine and Irinotecan With or Without Amifostine in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
A Combination Study to Evaluate the Safety and Efficacy of an Anticancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Gastrointestinal Cancer
A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Solid Tumors
100 Clinical Results associated with Amifostine
Login to view more data
100 Translational Medicine associated with Amifostine
Login to view more data
100 Patents (Medical) associated with Amifostine
Login to view more data
1,841
Literatures (Medical) associated with Amifostine01 Jan 2025PHYTOMEDICINE
Multi-omics analysis reveals the protective effects of Chinese yam polysaccharide against cisplatin-induced renal interstitial fibrosis
Article
Author: Chen, Shurui ; Yang, Yufang ; Wei, Meizhen ; Huang, Zhenguang ; Chen, Shasha ; Huang, Zhiling ; Chen, Xingqing ; Wan, Peiyuan ; Zhang, Pingli
BACKGROUND:
Chinese yam polysaccharide (SYDT) has been reported to protect renal function and mitigate renal fibrosis in mice with diabetic nephropathy. Based on a multi-omics analysis, the objectives of this study were to determine the effect of SYDT on cisplatin (CDDP)-induced chronic renal interstitial fibrosis (RIF) and the underlying molecular mechanisms using an in vivo model.
METHODS:
Rats were intraperitoneally injected with a single dose of CDDP and then treated with SYDT or amifostine (AMF). The levels of urinary N-acetyl-β-d-glucosaminidase (NAG), blood urea nitrogen (BUN) and serum creatinine (Scr) were detected to assess renal function. Renal tissue damage and fibrosis were evaluated using hematoxylin and eosin (H&E) and Masson's trichrome staining, respectively. In addition, this study applied transcriptomics and metabolomics to predict the possible mechanism of SYDT action, which was verified by several relevant examinations.
RESULTS:
SYDT significantly protected the renal function, alleviated renal tissue damage and fibrosis, as well as decreased the protein levels of vimentin, α-SMA and CTGF, whereas SYDT significantly increased MMP-1 protein level in renal tissues from rats treated with CDDP. There were 1130 differently expressed genes (DEGs) between the CDDP model and SYDT-M groups proved by transcriptome analysis, indicating that metabolic pathways were likely the primary targets of relevance. Consistent with the transcriptome analysis, metabolome analysis identified 276 differentially expressed metabolites (DEMs) between the SYDT-M and CDDP model groups, with predominant clustering within glycerophospholipid metabolism. Integrative analysis of the transcriptome and metabolome indicated that SYDT inhibited the glycerophospholipid metabolism pathway by regulating the target genes Gpd2, Gpam, Agpat3, Lcat, and Pla2g4b. Notably, integrative analysis showed that the Phospholipase D (PLD) signaling pathway may be the most relevant target. Moreover, related signaling pathway analysis confirmed that SYDT inhibited CDDP-induced RIF in rats by down-regulating the PLD pathway.
CONCLUSION:
Our study showed that the alleviation of CDDP-induced RIF in vivo can be achieved through the inhibition of glycerophospholipid metabolism and PLD signaling pathways by SYDT.
01 Dec 2024EJSO
Acute kidney injury after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A systematic review
Review
Author: Kuberkar, Deepali V ; Kuberkar, Deepali V. ; Solanki, Sohan Lal ; Bhatt, Aditi ; Ambulkar, Reshma ; Salunke, Bindiya ; Gangakhedkar, Gauri
The use of nephrotoxic chemotherapeutic agents during hyperthermic intraperitoneal chemotherapy (HIPEC), carries the risk of postoperative acute kidney injury (AKI). The available evidence on this subject is sparse with variability in the reported incidence of AKI. In this systematic review, the aim was to analyse the incidence, risk factors, and preventive measures for AKI after cytoreductive surgery and HIPEC. A systematic literature search was conducted using the terms 'Acute kidney injury', 'Acute kidney failure', 'Acute renal failure', 'Acute renal impairment', 'HIPEC Surgery', 'Cytoreductive Surgery', 'Heated Chemotherapy' on PubMed, Scopus, clinical trial.gov, POPLINE and Google Scholar. Randomized controlled trials, cohort studies and observational studies published from January 2000-December 2020 were included. The systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021247781). Data from 16 articles, which included 1622 patients, was included. The incidence AKI by any definition, was 23.36 %. The highest incidence of AKI (45.45 %) was reported after paclitaxel-HIPEC. The incidence of AKI after cisplatin-HIPEC was 34.7 %. Cisplatin HIPEC was the most common factor associated with AKI in 7/16 studies followed by pre-existing comorbidities and low intraoperative diuresis in 4 and 3 studies respectively. The perioperative use of sodium thiosulfate and amifostine led to a significant reduction in the incidence of AKI. The reported incidence of AKI after CRS-HIPEC is high. Identifying preoperative risk factors, optimising comorbidities, maintaining perioperative haemodynamic stability, perioperative use of sodium thiosulfate, maintaining adequate diuresis could reduce the incidence of AKI.
03 Oct 2024NEURO-ONCOLOGY
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma
Article
Author: McAleer, Mary Frances ; Brown, Austin L ; Lindsay, Holly B ; Su, Jack M ; Chintagumpala, Murali M ; Abu-Arja, Mohammad H ; Paulino, Arnold C ; Grosshans, David R ; Okcu, M Fatih ; McGovern, Susan L
Abstract:
Background:
Hearing loss (HL) is associated with worse neurocognitive outcomes among patients with medulloblastoma. We aimed to identify risk factors associated with severe HL and to evaluate the generalizability of a published HL calculator among patients treated with passive scattering proton therapy (PSPT) and cisplatin.
Methods:
We identified patients aged 3–21 years who were treated at our centers between 2007 and 2022. Audiograms were graded using the International Society of Pediatric Oncology (SIOP) Boston scale. Time to grades 3–4 HL was evaluated using Kaplan–Meier and multivariable Cox models to estimate hazard ratios and 95% confidence intervals (CI).
Results:
Seventy-nine patients were treated with PSPT at a median age of 7.5 years (range: 3.1–21.1). The mean cochlear dose (Dmc) (±SD) was 31.5 ± 8.5 Gy, and the cumulative cisplatin dose was 295 ± 50 mg/m2. Fifty-nine patients (75%) received amifostine. Patients completed a median of 9 audiograms (range: 4–22) with a median audiogram follow-up of 49 months (range: 6–177). Twenty-seven patients (34%) had grades 3–4 HL. In adjusted Cox models, only higher Dmc (HR = 1.12, 95% CI:1.06–1.18) was associated with grades 3–4 HL. The predicted 3-year incidence of grades 3–4 HL was 40.0% (95% CI: 21.3–66.3) and 66.7% (95% CI: 35.4–93.7) for children with Dmc ≥36 Gy and age at radiotherapy ≥7 and <7 years, respectively (P = .042). It was 8.9% (95% CI: 2.3–31.6) and 15.6% (95% CI: 5.3–41.1) for children with Dmc <36 Gy and age at radiotherapy ≥7 and <7 years, respectively (P = .78).
Conclusions:
Children <7 years at radiotherapy with a Dmc ≥36 Gy are at higher risk for HL.
2
News (Medical) associated with Amifostine11 Aug 2023
AcquisitionLicense out/in
10 Aug 2023
AcquisitionRadiation Therapy
100 Deals associated with Amifostine
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00226 | Amifostine |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Cytoprotective Agent | CN | 01 Jan 2001 | |
| Neutropenia | AU | 16 Apr 1998 | |
| Xerostomia | AU | 16 Apr 1998 | |
| Chemotherapy-induced damage | US | 08 Dec 1995 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Head and Neck Neoplasms | Phase 3 | FR | 01 Mar 2001 | |
| Colorectal Cancer | Phase 2 | US | 01 Oct 2006 | |
| Acute Myeloid Leukemia | Phase 2 | US | 01 Jul 2004 | |
| Acute Myeloid Leukemia | Phase 2 | IL | 01 Jul 2004 | |
| Esophagitis | Phase 2 | US | 01 Nov 2003 | |
| Pneumonia | Phase 2 | US | 01 Nov 2003 | |
| Unresectable Lung Non-Small Cell Carcinoma | Phase 2 | US | 01 Nov 2003 | |
| Hodgkin's Lymphoma | Phase 2 | US | 01 May 2003 | |
| Non-Hodgkin Lymphoma | Phase 2 | US | 01 May 2003 | |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | US | 01 May 2002 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 4 | vpoxduedld(lfkfayvbyt) = nyuvfuktfo uuwatgrstf (fngsxdfgss, oxmviteelq - efkeiqlyil) View more | - | 01 Aug 2023 | |||
Phase 2 | 2 | oegdvrxpmq(xjwuhaifvy) = nibwfczffg vfyhmncluf (dplyuckkwf, mpngoxoukq - pnknilryls) View more | - | 25 Jan 2022 | |||
Phase 3 | 17 | CyberKnife stereotactic radiosurgery (Placebo) | caysgbpfxi(anplftoxzi) = acewzoeaqi kfaksfgvne (xugfwwxzys, jnflwjgixo - pwreyxpwka) View more | - | 04 Apr 2017 | ||
(Amifostine) | caysgbpfxi(anplftoxzi) = dnjmatzwhc kfaksfgvne (xugfwwxzys, ikcdueczpw - fjsctuarpn) View more | ||||||
Phase 2 | 21 | mzsutifgky(kjishihmmu) = cvhlimarip cmqoldchml (fskqdavaes, nuoijjjrpj - goefqilzlp) View more | - | 08 Aug 2016 | |||
Not Applicable | 50 | (IMRT) | nznqftbaer(pwfziqftyv) = famkgjjlzk sviycswpxb (vccyrjycpi ) View more | Positive | 01 Nov 2010 | ||
Conventional Radiotherapy with Amifostine | nznqftbaer(pwfziqftyv) = zdsfyyuedl sviycswpxb (vccyrjycpi ) | ||||||
Phase 2 | 3 | Intensity- Modulated Radiation Therapy+Amifostine | oqodoqsbra(dbyziwtkjd) = keltwbdwxg bexietlftx (idtakuvvrs, rgqtyofuzc - ufjosdamsf) View more | - | 18 Jan 2010 | ||
Phase 2 | 58 | Carboplatin/paclitaxel + Amifostine | hzxyxcmtkz(xiepgazafs) = xlznuleenh ffppfnpmzl (aasgnubcer ) | - | 01 Oct 2009 | ||
Not Applicable | - | - | Amifostine 340mg/m^2 | gzlckvezcn(irhudaendt) = gbivdrqyww gkjloqoyis (jjqvfpvsom, (0.11 - 0.17)) | - | 01 Sep 2008 | |
Not Applicable | 193 | resuolbheh(tohiaibjae) = mwpbmjsrad cvitxuhgsq (pkcynihzho ) View more | Negative | 01 Nov 2007 | |||
Control (no Amifostine) | resuolbheh(tohiaibjae) = niixfxkysl cvitxuhgsq (pkcynihzho ) View more | ||||||
Not Applicable | Consolidation | 44 | riljkhflds(ucgbqegmdr) = zzypmuskup jbfqcmvmsh (qobkxsvcwt ) View more | Positive | 01 Nov 2007 | ||
heiikraevk(wybznfimce) = bzberuxnil wyfeqcjnkv (hcqzgoujgq ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free